Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
An article from
News roundup
Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, a prolific university advanced a new ebola vaccine.
Published July 13, 2026
Getty Images
Why Is Agenus Stock Gaining Monday? - Agenus (NASDAQ:AGEN)
Why Is Agenus Stock Falling on Tuesday? - Agenus (NASDAQ:AGEN)
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO…
Agenus Inc. (Nasdaq: AGEN) , leader nell’innovazione in campo immuno-oncologico, ha annunciato oggi i dati di riferimento…
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron…
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's…
